Edition:
India

Chromadex Corp (CDXC.OQ)

CDXC.OQ on NASDAQ Stock Exchange Capital Market

4.89USD
10:21pm IST
Change (% chg)

$0.12 (+2.52%)
Prev Close
$4.77
Open
$4.79
Day's High
$4.89
Day's Low
$4.76
Volume
24,545
Avg. Vol
145,453
52-wk High
$5.79
52-wk Low
$2.50

Latest Key Developments (Source: Significant Developments)

Chromadex Corporation Reports Second Quarter 2020 Financial Results
Friday, 7 Aug 2020 

Aug 6 (Reuters) - Chromadex Corp ::ORATION REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.06.Q2 SALES $15.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $13.9 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.IMPACT OF COVID-19 ON REVENUES IS DIFFICULT TO PREDICT.MANAGING EXPENSES TO MITIGATE BOTTOM-LINE IMPACT.DOES NOT EXPECT ANY SUPPLY CHAIN DISRUPTION AT THIS TIME.BASED ON TRENDS-TO-DATE, EXPECTS CONTINUED REVENUE GROWTH THIS YEAR.  Full Article

Chromadex And NIH-NIAID Rocky Mountain Laboratories Announce Study To Assess Therapeutic Potential Of Niagen® In Covid-19 Animal Models
Tuesday, 7 Jul 2020 

July 7 (Reuters) - Chromadex Corp ::CHROMADEX AND THE NIH-NIAID ROCKY MOUNTAIN LABORATORIES ANNOUNCE STUDY TO ASSESS THE THERAPEUTIC POTENTIAL OF NIAGEN® IN COVID-19 ANIMAL MODELS.CHROMADEX CORP - STUDY ON CHROMADEX'S NR INGREDIENT TO BE CONDUCTED AT NIH-NIAID'S ROCKY MOUNTAIN LABS.  Full Article

ChromaDex Says An R&D Facility In Colorado Earns Accredition
Wednesday, 17 Jun 2020 

June 17 (Reuters) - ChromaDex::CHROMADEX SAYS ITS RESEARCH AND DEVELOPMENT FACILITY IN LONGMONT, COLORADO ACHIEVED A QUALITY STANDARD FOR LABORATORY TESTING.  Full Article

Chromadex Says Selling Stockholders Offer And Resale Of Up To 1.23 Mln Shares Of Common Stock
Wednesday, 3 Jun 2020 

June 3 (Reuters) - Chromadex Corp ::CHROMADEX CORP SAYS SELLING STOCKHOLDERS OFFER AND RESALE OF UP TO 1.23 MILLION SHARES OF COMMON STOCK - SEC FILING.  Full Article

Chromadex Files For Offering Of Up To 1.23 Million Shares Of Common Stock By Selling Stockholders
Friday, 22 May 2020 

May 21 (Reuters) - Chromadex Corp ::CHROMADEX CORP FILES FOR OFFERING OF UP TO 1.23 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.  Full Article

ChromaDex Corporation Reports Q1 Loss Per Share $0.10
Tuesday, 12 May 2020 

May 11 (Reuters) - Chromadex Corp ::ORATION REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.10.Q1 SALES $14.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $13.8 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.  Full Article

Chromadex Posts Quarterly Loss Per Share Of $0.15
Wednesday, 11 Mar 2020 

March 10 (Reuters) - Chromadex Corp ::ORATION REPORTS 2019 FINANCIAL RESULTS.Q4 NON-GAAP LOSS PER SHARE $0.11 EXCLUDING ITEMS.Q4 LOSS PER SHARE $0.15.Q4 SALES $13.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $12.9 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.  Full Article

Chromadex Posts Q3 Sales of $12.1 Million
Wednesday, 13 Nov 2019 

Nov 12 (Reuters) - Chromadex Corp ::ORATION REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.12.Q3 SALES $12.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $11.6 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.12 -- REFINITIV IBES DATA.SEES 2019 REVENUE GROWTH TO BE DRIVEN PRIMARILY BY ITS U.S. ECOMMERCE AND WATSONS INTERNATIONAL BUSINESS.  Full Article

ChromaDex Statement Regarding The Oct.9 Order In The Central District Of California Litigation
Friday, 11 Oct 2019 

Oct 11 (Reuters) - Chromadex Corp ::CHROMADEX STATEMENT REGARDING THE OCTOBER 9TH ORDER IN THE CENTRAL DISTRICT OF CALIFORNIA LITIGATION.CHROMADEX CORP - COMMENTS ON LATEST ORDER FROM CALIFORNIA COURT REGARDING ONGOING LITIGATION WITH ELYSIUM.CHROMADEX CORP - LOOK FORWARD TO ANSWERING JUDGE'S QUESTIONS.CHROMADEX - WILL CONTINUE TO ENFORCE INTELLECTUAL PROPERTY RIGHTS IN PENDING INFRINGEMENT CASE REGARDING PATENTS ELYSIUM UNSUCCESSFULLY CHALLENGED.  Full Article

Chromadex Q1 Loss Per Share $0.15
Friday, 10 May 2019 

May 9 (Reuters) - Chromadex Corp ::ORATION REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.15.Q1 SALES $10 MILLION VERSUS REFINITIV IBES ESTIMATE OF $9.6 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.12 -- REFINITIV IBES DATA.EXPECTS TO BE CASH FLOW BREAKEVEN BY Q4 OF 2019 OR EARLY 2020..  Full Article

BRIEF-Chromadex And NIH-NIAID Rocky Mountain Laboratories Announce Study To Assess Therapeutic Potential Of Niagen® In Covid-19 Animal Models

* CHROMADEX AND THE NIH-NIAID ROCKY MOUNTAIN LABORATORIES ANNOUNCE STUDY TO ASSESS THE THERAPEUTIC POTENTIAL OF NIAGEN® IN COVID-19 ANIMAL MODELS